Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon Jun 07, 2018 1:04pm
77 Views
Post# 28140394

That Looks Better Re -Released Again Stockwatch !

That Looks Better Re -Released Again Stockwatch !

 

Diagnos launches diabetes screening facility in Quebec

 

2018-06-07 12:47 ET - News Release

 

Mr. Andre Larente reports

DIAGNOS PRESENTS A TECHNOLOGICAL SHOWCASE AT THE CHUM

Diagnos Inc. has created a technological showcase at the Centre Hospitalier of the University of Montreal (CHUM) with the opening of an automated screening clinc for diabetic retinopathy assisted by artificial intelligence.

Technological showcase

Diagnos thanks the Quebec government for $159,335 in funding through the Creativite Quebec program. This amount will support a $398,337 technological showcase project conducted in conjunction with the ophthalmology and endocrinology departments of CHUM. The announcement was made today by Dominique Anglade, Deputy Premier, Minister of Economy, Science and Innovation, and the minister responsible for the digital strategy, Gaetan Barrette, member of the National Assembly for La Piniere and Minister of Health and Social Services, and Lucie Charlebois, Minister for Rehabilitation, Youth Protection, Public Health and Healthy Living and the minister responsible for the Monteregie region.

"The technology developed by Diagnos provides a rapid detection of serious health problems with the use of artificial intelligence. This technological showcase will demonstrate the efficiency of their technology in real-life conditions. I praise the collaboration of CHUM, which can take advantage of the results of this project, benefitting the patients." said Mr. Barrette, member for La Piniere and Minister of Health and Social Services.

Please refer to the press release from Quebec's Ministry of Economy, Science and Innovation.

AI for detection and triage

Diagnos's early detection service includes an automated AI analysis of fundus imagery together with a triage system according to the degree of severity. This service is available on the company's CARA telehealth platform (computer-assisted retina analysis), which has been certified by both Health Canada and the Food and Drug Administration in the United States.

Improving patient services

The Diagnos automated screening solution significantly increases accessibility for diabetic and hypertensive patients subject to annual screening. Screening is done at the service centre using fundus photography. The process is fast, painless, and very simple for the patient. The CARA platform will facilitate identification and speedy triage of patients suffering from retinopathies who have been referred to the ophthalmology department following a consultation at the endocrinology or diabetes clinic.

"We are very pleased to have the support of the government of Quebec for this technological showcase. We are especially privileged to collaborate with a prestigious and groundbreaking institution such as the Centre Hospitalier de l'Universite de Montreal. We are particularly grateful to the endocrinologists and ophthalmologists who are supporting this first automated screening facility in Canada using artificial intelligence to offer wide-scale screening to diabetic patients," said Andre Larente, president of DIAGNOS.

About Diagnos Inc.

Diagnos is present in 15 countries and has screened more than 222,000 diabetic patients. Thanks to the support of the government of Quebec and the company's collaboration with the CHUM, this technological showcase will allow it to demonstrate its expertise at home. It will also help set up extensive screening campaigns in other Canadian provinces and in the United States. To support its growth, the company plans on hiring 10 employees at its headquarters in Brossard.

About compute-assisted retinal analysis

CARA is a teleophthalmology platform that integrates with current (material and IT) tools and processes at the point of intervention and comprises the following elements: image download, image enhancement, automated prescreening, categorization by an expert, and referral to a specialist. CARA's image enhancement algorithms, which use Diagnos's Flaire AI technology, allow the company to obtain sharper and clearer traditional retinal images which are easier to analyze. CARA can be used safely over the Internet and is compatible with all brands of retinographs, all standard image formats, and DME. It is a cost-effective tool for real-time screening of large numbers of patients and has been approved by regulatory bodies in Canada (Health Canada), the United States (Food and Drug Administration), Europe and elsewhere.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.


Bullboard Posts